Escitalopram for Agitation in Alzheimer's Disease

Trial Profile

Escitalopram for Agitation in Alzheimer's Disease

Phase of Trial: Phase III

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Escitalopram (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Acronyms S-CitAD
  • Most Recent Events

    • 08 Jun 2018 Planned End Date changed from 1 Mar 2021 to 1 Aug 2022.
    • 08 Jun 2018 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2021.
    • 11 Dec 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top